Apr 01, 2014 7:35 am EDT Heat Biologics, Inc. Reports 2013 Fourth Quarter and Full Year Financial Results
Mar 26, 2014 4:15 pm EDT Heat Biologics, Inc. to Present at the MaidStone Life Sciences Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, March 27, 2014
Mar 19, 2014 8:00 am EDT Heat Biologics, Inc. Submits Revised Protocol to FDA for Phase 2 Clinical Study of HS-110 for the Treatment of Non-Small Cell Lung Cancer
Mar 10, 2014 8:05 am EDT Heat Biologics, Inc. Presents Preclinical Data From Comparative Combination Cancer Immunotherapy Research Study at Keystone Symposia on Immune Evolution in Cancer
Mar 05, 2014 8:05 am EST Heat Biologics, Inc. Appoints Taylor H. Schreiber, M.D., PH.D. as Vice President of Research and Development
Mar 03, 2014 8:05 am EST Heat Biologics Commences Dosing of First Patient in Phase 1/2 Study of Novel Cancer Immunotherapy Product Candidate HS-410 for the Treatment of Bladder Cancer
Feb 04, 2014 8:05 am EST Heat Biologics, Inc. to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014
Feb 03, 2014 8:35 am EST Heat Biologics, Inc. Announces Formation of Clinical Advisory Board With Preeminent Immunotherapy and Oncology Experts
Jan 17, 2014 8:05 am EST Heat Biologics, Inc. to Present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference on Tuesday, January 21, 2014